Abstract
Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer’s dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.
Keywords: Alzheimer’s dementia, amyotrophic lateral sclerosis, biomarker, case-control study, cerebrospinal fluid, frontotemporal dementia, GRN, progranulin, serum.
Current Alzheimer Research
Title:Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Volume: 13 Issue: 6
Author(s): Carlo Wilke, Frank Gillardon, Christian Deuschle, Evelyn Dubois, Markus A. Hobert, Jennifer Müller vom Hagen, Stefanie Krüger, Saskia Biskup, Cornelis Blauwendraat, Michael Hruscha, Stephan A. Kaeser, Peter Heutink, Walter Maetzler and Matthis Synofzik
Affiliation:
Keywords: Alzheimer’s dementia, amyotrophic lateral sclerosis, biomarker, case-control study, cerebrospinal fluid, frontotemporal dementia, GRN, progranulin, serum.
Abstract: Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer’s dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.
Export Options
About this article
Cite this article as:
Wilke Carlo, Gillardon Frank, Deuschle Christian, Dubois Evelyn, Hobert A. Markus, Hagen Müller vom Jennifer, Krüger Stefanie, Biskup Saskia, Blauwendraat Cornelis, Hruscha Michael, Kaeser A. Stephan, Heutink Peter, Maetzler Walter and Synofzik Matthis, Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160314151247
DOI https://dx.doi.org/10.2174/1567205013666160314151247 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Unfolded Protein Response in Chronic Obstructive Pulmonary Disease: Smoking, Aging and Disease: A SAD Trifecta
Current Molecular Medicine Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-Inflammatory Lipid Mediator)
CNS & Neurological Disorders - Drug Targets Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets RNA Interference: New Therapeutics in Allergic Diseases
Current Gene Therapy Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Genetically-Modified Human Pluripotent Stem Cells: New Hopes for the Understanding and the Treatment of Neurological Diseases?
Current Gene Therapy Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research